142 related articles for article (PubMed ID: 32442860)
1. Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 cases.
Thomas de Montpréville V; Lacroix L; Rouleau E; Mamodaly M; Leclerc J; Tutuianu L; Planchard D; Boulate D; Mercier O; Besse B; Fadel É; Ghigna MR
Ann Diagn Pathol; 2020 Jun; 46():151522. PubMed ID: 32442860
[TBL] [Abstract][Full Text] [Related]
2. An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma.
Kim Y; Ahn B; Yoon S; Lee G; Kim D; Chun SM; Kim HR; Jang SJ; Hwang HS
PLoS One; 2023; 18(6):e0287256. PubMed ID: 37347751
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
4. Miliary brain metastases from lung adenocarcinoma with EGFR (L858R) and CTNNB1 mutations.
Kunishige M; Takeuchi E
Thorac Cancer; 2023 Dec; 14(34):3419-3420. PubMed ID: 37920971
[TBL] [Abstract][Full Text] [Related]
5. EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.
Mraihi Z; Ben Amar J; Bouacha H; Rammeh S; Hila L
BMC Pulm Med; 2018 Aug; 18(1):132. PubMed ID: 30092812
[TBL] [Abstract][Full Text] [Related]
6. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
[TBL] [Abstract][Full Text] [Related]
8. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies.
Ho HL; Kao HL; Yeh YC; Chou TY
Diagn Pathol; 2019 Jun; 14(1):59. PubMed ID: 31221183
[TBL] [Abstract][Full Text] [Related]
9. Distinctive Patterns of CTNNB1 (β-Catenin) Alterations in Salivary Gland Basal Cell Adenoma and Basal Cell Adenocarcinoma.
Jo VY; Sholl LM; Krane JF
Am J Surg Pathol; 2016 Aug; 40(8):1143-50. PubMed ID: 27259009
[TBL] [Abstract][Full Text] [Related]
10. [Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer].
Fan MJ; Li HG; Lü ZQ; Zhang HZ; Shen XM
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):679-82. PubMed ID: 22321547
[TBL] [Abstract][Full Text] [Related]
11. Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.
Bonnet S; Gaujoux S; Launay P; Baudry C; Chokri I; Ragazzon B; Libé R; René-Corail F; Audebourg A; Vacher-Lavenu MC; Groussin L; Bertagna X; Dousset B; Bertherat J; Tissier F
J Clin Endocrinol Metab; 2011 Feb; 96(2):E419-26. PubMed ID: 21084400
[TBL] [Abstract][Full Text] [Related]
12. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
[TBL] [Abstract][Full Text] [Related]
13. [Detection of epidermal growth factor receptor mutations in non-small-cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types].
Sun MH; Yang F; Shen L; Zhang L; Chen Y; Cai X; Zhu XL; Zhou XY
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):655-9. PubMed ID: 22321541
[TBL] [Abstract][Full Text] [Related]
14. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Clinical Profile of EGFR Mutation In Non- Small-Cell Lung Carcinoma Patients in Southwest China.
Zhou J; Song XB; He H; Zhou Y; Lu XJ; Ying BW
Asian Pac J Cancer Prev; 2016; 17(3):965-71. PubMed ID: 27039821
[TBL] [Abstract][Full Text] [Related]
16. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
[TBL] [Abstract][Full Text] [Related]
17. ALK fusion and its association with other driver gene mutations in Finnish non-small cell lung cancer patients.
Tuononen K; Kero M; Mäki-Nevala S; Sarhadi VK; Tikkanen M; Wirtanen T; Rönty M; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2014 Nov; 53(11):895-901. PubMed ID: 24942490
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations.
Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R
Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population.
Skov BG; Høgdall E; Clementsen P; Krasnik M; Larsen KR; Sørensen JB; Skov T; Mellemgaard A
APMIS; 2015 Feb; 123(2):108-15. PubMed ID: 25421919
[TBL] [Abstract][Full Text] [Related]
20. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.
Bläker H; Helmchen B; Bönisch A; Aulmann S; Penzel R; Otto HF; Rieker RJ
Scand J Gastroenterol; 2004 Aug; 39(8):748-53. PubMed ID: 15513360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
